Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.

Scientific reports - 21 Apr 2020

Alonso-Alonso Ruth, Mondéjar Rufino, Martínez Nerea, García-Diaz Nuria, Pérez Cristina, Merino David, Rodríguez Marta, Esteve-Codina Anna, Fuste Berta, Gut Marta, Burrows Francis, Scholz Catherine, Vaqué Jose Pedro, Gualberto Antonio, Piris Miguel Ángel

Abstract excerpt

Patients diagnosed with T-cell leukemias and T-cell lymphomas (TCLs) still have a poor prognosis and an inadequate response to current therapies, highlighting the need for targeted treatments. We have analyzed the potential therapeutic value of the farnesyltransferase inhibitor, tipifarnib, in 25 TCL cell lines through the identification of genomic and/or immunohistochemical markers of tipifarnib sensitivity....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Cell Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Gene Expression Regulation, Leukemic

Share to Inhibitory Concentration 50

Share to Lymphoma, T-Cell

Share to Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 32317694
DOI: 10.1038/s41598-020-63434-5
PMCID: PMC7174413

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.PMID 32317694Read ↗

Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines.Semantic proximity Read ↗

In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.Semantic proximity Read ↗

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.Semantic proximity Read ↗

Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib.Semantic proximity Read ↗

Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphomaSemantic proximity Read ↗

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemiaSemantic proximity Read ↗

EFNB1 level affects drug response in DLBCL cell linesSemantic proximity Read ↗

T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to ChemotherapySemantic proximity Read ↗

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphomaSemantic proximity Read ↗

Proteomic profiling reveals pleiotropic antimetabolite activity of triciribine in acute lymphoblastic leukemiaSemantic proximity Read ↗

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.Semantic proximity Read ↗

Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.